



Investigators at Ann & Robert H. Lurie Children's Hospital (Lurie Children's)
invite you to consider participating in a research study:

A Phase 3, Double Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYN1934 in Patients with PKU (SYNPHENY-3)

Sponsored by: Synlogic Operating Company, Inc. and carried out by Erika Vucko, APRN.

Dear Potential Participant:

The research team at Lurie Children's Hospital is reaching out to let you know about A Phase 3, Double Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYN1934 in Patients with PKU (SYNPHENY-3). We are currently recruiting adults (ages 18 and older) who have PKU for this research study.

The purpose of this study is to learn about the effects (good and/or bad) SYN1934 has on adults and their PKU. More specifically, this study will help us learn if SYN1934 is safe in controlling blood Phe levels in adults. SYN1934 is a probiotic power product that will be ingested through mixing it with water or apple juice or a combination of both. This study is broken into three separate parts that will lead to an open label extension study. You will need to complete one part before moving onto the next part in the study. In Part 1, participants will find the right dose of the Investigational Medicinal Product (IMP) that their body tolerates. In Part 2, participants will have a 50 percent chance to be a part of one group will continue taking their confirmed dose of the IMP or another group that takes a placebo. In Part 3, all participants will find their tolerated dose again and enter an open label extension that will last up to 3 years.

If you are interested in learning more, please contact any of the research team members at the phone numbers or emails listed below.

Thank you and we look forward to hearing from you!

Sincerely,

Dejavette Yang
Clinical Research Coordinator
312.227.2481
dgyang@luriechildrens.org

Lindsey Lang
Clinical Research Coordinator
312.227.6712
llang@luriechildrens.org

Phillip Luu
Clinical Research Coordinator
312.227.6128
pluu@luriechildrens.org

This study is Lurie Children's IRB #2023-5926

A Phase 3, Double Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYN1934 in Patients with PKU (SYNPHENY-3)

Principal Investigator: Erika Vucko, APRN

The content of this letter has been approved by the Lurie Children's IRB